Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry

Ageno, Walter; Haas, Sylvia; Weitz, Jeffrey I; Goldhaber, Samuel Z; Turpie, Alexander G G; Goto, Shinya; Angchaisuksiri, Pantep; Dalsgaard Nielsen, Joern; Kayani, Gloria; Farjat, Alfredo E; Zaghdoun, Audrey; Schellong, Sebastian; Bounameaux, Henri; Mantovani, Lorenzo G; Prandoni, Paolo; Darius, Harald; Kakkar, Ajay K

doi:10.1055/s-0039-1688828

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry
Authors		Ageno, Walter Haas, Sylvia Weitz, Jeffrey I Goldhaber, Samuel Z Turpie, Alexander G G Goto, Shinya Angchaisuksiri, Pantep Dalsgaard Nielsen, Joern Kayani, Gloria Farjat, Alfredo E Zaghdoun, Audrey Schellong, Sebastian Bounameaux, Henri Mantovani, Lorenzo G Prandoni, Paolo Darius, Harald Kakkar, Ajay K show all authors [1 - 17]
Published in		Thrombosis and Haemostasis. 2019, vol. 119, no. 8, p. 1365-1372
Abstract		Upper extremity deep vein thrombosis (UEDVT) is less common than lower extremity DVT (LEDVT) and consequently less well characterized. This study compared clinical characteristics and 1-year outcomes between 438 UEDVT patients and 7,602 LEDVT patients recruited in the GARFIELD-VTE registry. UEDVT patients were significantly more likely to have a central venous catheter than those with LEDVT (11.5% vs. 0.5%; p < 0.0001), and had a higher rate of active cancer (16.2%) or recent hospitalization (19.4%) compared with LEDVT patients (8.7% and 11.2%, respectively). Nearly all patients with UEDVT and LEDVT were initiated on anticoagulant therapy, which was a direct oral anticoagulant in one-third individuals in both groups. At 3, 6, and 12 months, the proportion of UEDVT and LEDVT patients who were receiving anticoagulant therapy was 82.6 and 87.4%, 66.0 and 72.6%, and 45.7 and 54.6%, respectively. In the UEDVT and LEDVT groups, VTE recurrence rate was 4.0 (95% confidence interval [CI], 2.4-6.7) and 5.5 (95% CI, 4.9-6.1) per 100 person-years, respectively; major bleed was noted in 1.3 (95% CI, 0.6-3.2) and 1.6 (95% CI, 1.3-1.9) per 100 person-years and all-cause mortality in 9.7 (95% CI, 7.1-13.4) and 6.7 (95% CI, 6.1-7.3) per 100 person-years, respectively. Hence, risk of recurrence was similar in the two groups whereas all-cause mortality was significantly higher in the UEDVT group than the LEDVT group (p = 0.0338). This latter finding was likely due to the high prevalence of cancer in the UEDVT group.
Keywords		Upper extremity deep vein thrombosis — lower extremity deep vein thrombosis — direct oral anticoagulant — venous thromboembolism — GARFIELD-VTE registry
Identifiers		DOI: 10.1055/s-0039-1688828 PMID: 31183844
Full text		Article (Published version) (214 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research group		La maladie thromboembolique veineuse (808)
Citation (ISO format)		AGENO, Walter et al. Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. In: Thrombosis and Haemostasis, 2019, vol. 119, n° 8, p. 1365-1372. doi: 10.1055/s-0039-1688828 https://archive-ouverte.unige.ch/unige:133080